NYU Langone Health Halts Transgender Program for Minors

NYU Langone Health, a prominent hospital in Manhattan, has decided to discontinue its transgender program for minors, citing concerns over federal funding threats.

In a statement, the hospital explained, “Given the recent resignation of our medical director and the current regulatory environment, we have made the difficult decision to discontinue the Transgender Youth Health Program.” This announcement has raised some eyebrows, given the current landscape of healthcare for transgender youth.

The link to the hospital’s Transgender Youth Health Program leads to information on “Gender and Sexuality Services,” which emphasizes support for children and their families in understanding their identities and achieving mental wellness. Yet, recent discussions suggest a significant shift is underway, especially regarding hormones and other treatments for transgender youth.

Manhattan Borough President Brad Hoylman-Segal expressed concern about the implications of this decision. He stated that he believes it’s critical to find alternative treatments quickly, emphasizing that it’s the hospital’s duty to aid in this transition.

This isn’t an abrupt change for NYU Langone. According to reports, the hospital had already ceased accepting new patients into its transgender youth program last year. This pause followed the issuance of an executive order by President Donald Trump focused on protecting minors from certain medical procedures. The hospital had even canceled appointments for new patients needing puberty blockers.

In December 2025, the Department of Health and Human Services renewed its efforts with proposed rules to prevent what it termed “child sex-denial practices,” aiming to block Medicaid funding for procedures performed on minors.

Further complicating matters, a recent case in New York highlighted the stakes involved. A woman sued her healthcare provider after undergoing a double mastectomy at the age of 16, arguing she wasn’t emotionally ready for such a decision. The jury awarded her a significant settlement, raising questions about how this might influence policies regarding transgender treatment in the future.

It’s unclear what these developments mean for transgender healthcare in New York state, especially as federal and local stances seem to be shifting.